Die R-Biopharm AG wurde 1988 als Tochterunternehmen der Röhm GmbH in Darmstadt gegründet und 1991 vom jetzigen Vorstand Dr. Ralf M. Dreher übernommen. 1996 wurde das Unternehmen nach DIN EN ISO 9001 zertifiziert. 2003 erfolgte die Zertifizierung nach der Qualitätsmanagement-Norm ISO 13485. Seit Januar 2000 besitzt die R-Biopharm AG weltweit die exklusiven Vertriebsrechte für die Enzymatische BioAnalytik der Firma Roche Diagnostics (ehemals Boehringer Mannheim). 2002 erfolgte die Übernahme der Firma Rhône Diagnostics Technologies in Schottland, einem Mitanbieter im Bereich Mykotoxin-Analytik. Hierdurch konnte R-Biopharm seine Position im Bereich Lebensmittel- & Futtermittelanalytik ausbauen. R-Biopharm ist durch seine Tochterfirmen in UK, den USA, Italien, Frankreich, Lateinamerika, Brasilien, Spanien, Australian und China sowie über ein weltweites, mehr als 80 Distributeure umfassendes Netzwerk repräsentiert. Darüber hinaus werden die Schweiz, Österreich und die Niederlande direkt vor Ort betreut.
Location: Germany, Hesse, Pfungstadt
Employees: 1001-5000
Phone: +49 6151 81020
Founded date: 1988
Investors 1
Mentions in press and media 7
| Date | Title | Description |
| 25.11.2022 | Flu tests from R-Biopharm also detect new virus variants | Darmstadt, November 25, 2022 – The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also r... |
| 19.07.2022 | R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories | Darmstadt, July 19, 2022 – As a fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. The biotechnology company R-Bioph... |
| 30.06.2022 | R-Biopharm is IVDR certified | The quality management system of the biotechnology company complies with the European in-vitro Diagnostic Regulation (IVDR) Darmstadt, June 30, 2022 – Quality orientation is an integral part of the culture and processes at R-Biopharm AG. Th... |
| 07.06.2022 | R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics | Gaining new market segments in clinical diagnostics – globally unique position as system supplier in laboratory diagnostics sector Darmstadt, June 7, 2022 – R-Biopharm AG, a leading German biotechnology company operating on a global scale, ... |
| 01.06.2022 | R-Biopharm announces test to detect monkeypox virus | Test for research purposes available soon Darmstadt, Germany, June 1, 2022 – R-Biopharm AG, a leading and globally operating biotechnology company based in Germany, will soon launch a test for the detection of monkeypox virus. The real-time... |
| 07.12.2021 | R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation | Darmstadt, 7 December 2021 – R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDA®GENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agenc... |
| 23.05.2010 | Zedira Raises Additional Funding | Zedira GmbH, a Darmstadt, Germany-based biotech company which focuses on celiac disease and consequently also on the transglutaminases family of enzymes, has recieved a minority investment from R-Biopharm AG. High-Tech Gründerfonds, which i... |